Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 12;12:1877–1886. doi: 10.2147/CMAR.S245525

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Fu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

RT-PCR verification of hsa_circRNA_012515 expressions in clinical tissue samples and cell lines. (A) Shows the expressions of hsa_circRNA_012515 in cancerous tissues and paracancerous tissues from NSCLC patients (N indicates paracancerous tissues; T indicates cancerous tissues, n=83); (B) Shows the expression of hsa_circRNA_012515 in patients of different tumor stages (N indicates paracancerous tissues, n=83; T(stage I–II), n=43; T(stage III–IV), n=40); (C) Shows the expressions of hsa_circRNA_012515 in Peripheral blood samples from gefitinib-resistant (n=35) and gefitinib-sensitive (n=25) NSCLC patients. (D) Shows the expressions of hsa_circRNA_012515 in the pulmonary epithelial cells, NSCLC cells and gefitinib-resistant NSCLC cell lines. All experiments were performed in triplicate. Data were expressed as mean±standard deviation. #Indicates significant difference as compared with the N group, *Indicates significant difference as compared with the T(gefitinib-sensitive) group, ***Indicates significant difference as compared with the BEAS-2B cell (P<0.05).